Clinical Trials Logo

Non-Hodgkin Lymphomas clinical trials

View clinical trials related to Non-Hodgkin Lymphomas.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT01078922 Terminated - Clinical trials for Non-Hodgkin Lymphomas

Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas

Start date: February 2010
Phase: Phase 2
Study type: Interventional

This is a phase II open label study that looks at the efficacy and toxicity of Ofatumumab monotherapy in patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). Patients will receive weekly infusions of Ofatumumab of 1000 mg each for 8 weeks (induction phase) followed by continuing the study drugs every other week in subsequent cycles (maintenance phase). Each 4 weeks of therapy will be calculated as one cycle. Treatment will continue until disease progression, toxicity, patient's withdrawal, or investigator's discretion.